View ValuationODI Pharma 将来の成長Future 基準チェック /06現在、 ODI Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長37.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.すべての更新を表示Recent updatesReported Earnings • Nov 29First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025)First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024)Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.お知らせ • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025New Risk • Jul 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m).New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m).Reported Earnings • Feb 28Second quarter 2025 earnings released: kr0.17 loss per share (vs kr0.062 profit in 2Q 2024)Second quarter 2025 results: kr0.17 loss per share (down from kr0.062 profit in 2Q 2024). Revenue: kr74.0k (up kr72.9k from 2Q 2024). Net loss: kr2.56m (down 371% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025お知らせ • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.お知らせ • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights OfferingNew Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (kr48.7m market cap, or US$4.46m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m).Reported Earnings • Nov 24First quarter 2025 earnings released: kr0.096 loss per share (vs kr0.095 loss in 1Q 2024)First quarter 2025 results: kr0.096 loss per share (further deteriorated from kr0.095 loss in 1Q 2024). Revenue: kr251.3k (down 52% from 1Q 2024). Net loss: kr1.47m (loss widened 1.8% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.お知らせ • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023お知らせ • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.お知らせ • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023お知らせ • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jan 15ODI Pharma AB Proceeds with Its Plans and Launches Project SkinODI Pharma AB announced that the Board of Directors has decided to expand ODI's current business with specialized, highly CBD-infused skin care products. The Board of Directors sees Project Skin as a great platform to further build ODI Pharma's reputation and brand awareness. The products will be launched EU wide, with initial focus on a few markets, including Sweden. The Company will keep the market informed about the next step in the process.お知らせ • Nov 12ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020, at 10:00 Central European Standard Time. Location: Engelbrektsgatan 9-11 in Stockholm Stockholm Sweden Agenda: To consider Election of one or two persons to attest the minutes, where applicable; To consider Presentation of the annual report and auditor's report; To consider adoption of the income statement and the balance sheet and; To consider allocation of the company's profit or loss according to the adopted balance sheet; To consider discharge from liability for board members and the managing director; To consider amend the Articles of Association.お知らせ • Nov 03Odi Pharma AB and Aphria Inc. Execute Supply AgreementODI Pharma AB (publ) announced it has streamlined its supply chain and executed a Supply Agreement with Aphria Inc.'s wholly-owned German subsidiary, CC Pharma GmbH. The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; ·The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland.Is New 90 Day High Low • Oct 29New 90-day low: kr4.61The company is down 5.0% from its price of kr4.83 on 29 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ODI Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NGM:ODI - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202630022N/A12/31/202520-1-1-1N/A9/30/20259-5-4-4N/A6/30/20253-6-3-3N/A3/31/202511-6-7-7N/A12/31/202422-4-3-3N/A9/30/202422-100N/A6/30/202422-1-4-4N/A3/31/202415-2-1-1N/A12/31/20231-4-3-3N/A9/30/20231-7-5-5N/A6/30/20230-7-5-5N/A3/31/20230-7-5-5N/A12/31/20220-8-6-6N/A9/30/20220-8-7-7N/A6/30/20220-7-7-7N/A3/31/20221-7-7-7N/A12/31/20210-5-7-7N/A9/30/2021N/A-4-6-6N/A6/30/2021N/A-4-6-6N/A3/31/20210-3-7-7N/A12/31/20200-5-6-6N/A9/30/20200-6-7-7N/A6/30/2020N/A-5-5-5N/A3/31/20200-5-5-5N/A12/31/20190-3N/A-3N/A9/30/20190-3N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ODIの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ODIの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ODIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ODIの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ODIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ODIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 01:11終値2026/06/10 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ODI Pharma AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
Reported Earnings • Nov 29First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025)First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024)Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
お知らせ • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025
New Risk • Jul 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m).
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m).
Reported Earnings • Feb 28Second quarter 2025 earnings released: kr0.17 loss per share (vs kr0.062 profit in 2Q 2024)Second quarter 2025 results: kr0.17 loss per share (down from kr0.062 profit in 2Q 2024). Revenue: kr74.0k (up kr72.9k from 2Q 2024). Net loss: kr2.56m (down 371% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025
お知らせ • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.
お知らせ • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights Offering
New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (kr48.7m market cap, or US$4.46m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m).
Reported Earnings • Nov 24First quarter 2025 earnings released: kr0.096 loss per share (vs kr0.095 loss in 1Q 2024)First quarter 2025 results: kr0.096 loss per share (further deteriorated from kr0.095 loss in 1Q 2024). Revenue: kr251.3k (down 52% from 1Q 2024). Net loss: kr1.47m (loss widened 1.8% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024
Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024
Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
お知らせ • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024
Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024
Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023
お知らせ • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.
お知らせ • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023
Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023
お知らせ • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jan 15ODI Pharma AB Proceeds with Its Plans and Launches Project SkinODI Pharma AB announced that the Board of Directors has decided to expand ODI's current business with specialized, highly CBD-infused skin care products. The Board of Directors sees Project Skin as a great platform to further build ODI Pharma's reputation and brand awareness. The products will be launched EU wide, with initial focus on a few markets, including Sweden. The Company will keep the market informed about the next step in the process.
お知らせ • Nov 12ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020, at 10:00 Central European Standard Time. Location: Engelbrektsgatan 9-11 in Stockholm Stockholm Sweden Agenda: To consider Election of one or two persons to attest the minutes, where applicable; To consider Presentation of the annual report and auditor's report; To consider adoption of the income statement and the balance sheet and; To consider allocation of the company's profit or loss according to the adopted balance sheet; To consider discharge from liability for board members and the managing director; To consider amend the Articles of Association.
お知らせ • Nov 03Odi Pharma AB and Aphria Inc. Execute Supply AgreementODI Pharma AB (publ) announced it has streamlined its supply chain and executed a Supply Agreement with Aphria Inc.'s wholly-owned German subsidiary, CC Pharma GmbH. The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; ·The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland.
Is New 90 Day High Low • Oct 29New 90-day low: kr4.61The company is down 5.0% from its price of kr4.83 on 29 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.